Statins boost survival among seniors with rectal cancer
Using statins may improve survival among elderly adults with rectal cancer, a recent study has shown.
Researchers enrolled 465 elderly adults, who were categorized into two age groups: ≥70 years (n=238) and <70 years (n=227). Those who were using statins at the time of cancer diagnosis were designated as users, while those who weren’t were identified as nonusers. The primary study outcomes were cancer-specific (CSS), overall (OS) and disease-free (DFS) survival rates.
There were more nonusers than users at the time of rectal cancer diagnosis in both the younger (197 vs 30) and older (180 vs 58) age groups. The difference in the rate of use between groups was statistically significant (13 percent vs 24 percent, respectively; p=0.002).
In the older age group, statin use significantly increased CSS (adjusted hazard ratio [HR], 0.42, 95 percent CI, 0.21–0.84; p=0.013) and OS (adjusted HR, 0.59, 0.36–0.95; p=0.029) relative to nonuse. No such effect was reported for the younger age group (CSS: HR, 0.71, 0.31–1.66; p=0.429; OS: HR, 0.76, 0.38–1.53; p=0.445).
Similarly, statin use led to a significantly better DFS in participants in the older group with stage I–III disease (adjusted HR, 0.20, 0.06–0.65; p=0.008). No such effect was reported for the younger group (HR, 1.19, 0.53–2.69; p=0.668).
Statin use also significantly reduced the likelihood of distant recurrence in the older group (16 percent vs 36 percent; p=0.004) but not in the younger group (p=0.489). Statins had no influence on the risk of local recurrence.